NCT02253342

Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Wockhardt · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study to determine and compare plasma, epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of levonadifloxacin after administration of WCK 2349 in healthy adult subjects.

Conditions

• Intrapulmonary Pharmacokinetics of WCK 2349

Interventions

Type	Name	Description
DRUG	WCK-2349	Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1

Timeline

• Start date: 2014-09-01
• Primary completion: 2014-12-01
• Completion: 2015-08-01
• First posted: 2014-10-01
• Last updated: 2015-10-29

Locations

1 site across 1 country: United States